Zelira Therapeutics Ltd
G1G
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
8
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.20 | 5.20 | 0.06% |
| CAC 40 | 8,130.23 | 24.68 | -0.30% |
| DAX 40 | 25,384.72 | 194.13 | -0.76% |
| Dow JONES (US) | 51,863.69 | 185.14 | -0.36% |
| FTSE 100 | 10,690.63 | 17.70 | -0.17% |
| HKSE | 24,834.12 | 253.63 | -1.01% |
| NASDAQ | 27,244.28 | 122.18 | 0.45% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.76 | 53.72 | -0.39% |
| S&P 500 | 7,764.64 | 0.06 | -0.00% |
| S&P/ASX 200 | 8,765.30 | 7.50 | 0.09% |
| SSE Composite Index | 3,936.52 | 15.61 | -0.39% |